Noreen Scherer
Chief Tech/Sci/R&D Officer at LARIMAR THERAPEUTICS, INC.
Noreen Scherer active positions
| Companies | Position | Start | End |
|---|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2018-04-30 | - |
| Alcobra, Inc. | Chief Operating Officer | - | - |
Career history of Noreen Scherer
Former positions of Noreen Scherer
| Companies | Position | Start | End |
|---|---|---|---|
Chondrial Therapeutics, Inc.
 Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Chief Tech/Sci/R&D Officer | - | - |
Training of Noreen Scherer
| LaSalle University | Undergraduate Degree |
Statistics
International
| United States | 5 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Chief Operating Officer | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| LARIMAR THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Chondrial Therapeutics, Inc.
Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Alcobra, Inc. |
- Stock Market
- Insiders
- Noreen Scherer
- Experience
